These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27751675)

  • 21. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.
    Amin A; Keshishian A; Vo L; Zhang Q; Dina O; Patel C; Odell K; Trocio J
    J Med Econ; 2018 Mar; 21(3):244-253. PubMed ID: 29047304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization.
    Yamashita T; Laurent T; Kato M; Yoshihara N; Ono F
    J Med Econ; 2020 Dec; 23(12):1379-1388. PubMed ID: 32936057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
    Charlton B; Adeboyeje G; Barron JJ; Grady D; Shin J; Redberg RF
    PLoS One; 2018; 13(3):e0193912. PubMed ID: 29590141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
    Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
    Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.
    Groetzinger LM; Miller TJ; Rivosecchi RM; Smith RE; Gladwin MT; Rivera-Lebron BN
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):908-913. PubMed ID: 29455567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
    van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
    Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
    Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
    Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.